Back to top

Image: Bigstock

Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago

Read MoreHide Full Article

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.

Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.

What if you'd invested in Idexx Laboratories (IDXX - Free Report) ten years ago? It may not have been easy to hold on to IDXX for all that time, but if you did, how much would your investment be worth today?

Idexx Laboratories' Business In-Depth

With that in mind, let's take a look at Idexx Laboratories' main business drivers.

Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
IDEXX operates through four segments:

Companion Animal Group (CAG) (91.9% of revenues in 2025, up 10.6% from 2024): This segment provides veterinarians with diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The complementary nature of these products and services provides a unique competitive advantage known as the IDEXX Diagnostic Advantage, providing vets with the tools and services necessary to offer advanced veterinary medical care.

Water (4.7%, up 8.7%): Through this segment, IDEXX provides innovative testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping ensure water safety for people worldwide.

Livestock, Poultry and Dairy (LPD) (3.1%, up 8%): Within this segment, IDEXX provides diagnostic tests and related instrumentation required to manage the health status of livestock and poultry to improve bovine reproductive efficiency and ensure the quality and safety of milk and food. These products are purchased by the government and private laboratories that provide testing services to cattle, swine and poultry veterinarians, producers and processors.

Other (0.4%, up 7.3%): The company’s OPTI Medical operating segment has been combined and presented with the remaining pharmaceutical product line and the out-licensing arrangements in an Other category, primarily because they do not meet the quantitative or qualitative thresholds for reportable segments.

Bottom Line

Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Idexx Laboratories, ten years ago, you're likely feeling pretty good about your investment today.

A $1000 investment made in November 2016 would be worth $6,014.55, or a gain of 501.46%, as of November 19, 2026, according to our calculations. This return excludes dividends but includes price appreciation.

The S&P 500 rose 235.65% and the price of gold increased 193.70% over the same time frame in comparison.

Analysts are forecasting more upside for IDXX too.

IDEXX benefits from rising diagnostic utilization, an expanding premium instrument base and innovation across inVue Dx, Cancer Dx and Catalyst testing. International commercial expansion and connected software, including CoVet, create more opportunities for recurring revenue growth. Higher testing volumes, margin gains and healthy cash generation reinforce its competitive position. However, U.S. veterinary visits remain weak, particularly for wellness care, leaving growth reliant on continued gains in diagnostic adoption. Acquisition-related costs and commercial investment limit near-term margin expansion. Distributor purchasing patterns and foreign exchange movements add uncertainty to reported results. These competing factors support a balanced risk-reward profile despite sustained demand for advanced veterinary diagnostics.

Over the past four weeks, shares have rallied 26.20%, and there have been 6 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.

Published in